Gene · 3003
Papers2,892
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
721 to 740 of 2,892
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Development and validation of a novel M1 macrophage-related gene prognostic signature for lung cancer. | J Thorac Dis | 2023 | 37065568 | PubTator, text mining | PubMed |
| Etiology of end-stage liver cirrhosis impacts hepatic natural killer cell heterogenicity. | Front Immunol | 2023 | 37063898 | PubTator, text mining | PubMed |
| Phenotypic plasticity and reduced tissue retention of exhausted tumor-infiltrating T cells following neoadjuvant immunotherapy in head and neck cancer. | Cancer Cell | 2023 | 37059104 | PubTator, text mining | PubMed |
| Single-cell transcriptome analysis revealed the immune profile of PD-1 blockade in gallbladder carcinoma liver metastasis. | Hepatol Commun | 2023 | 37058121 | PubTator, text mining | PubMed |
| The progress of microenvironment-targeted therapies in brain metastases. | Front Mol Biosci | 2023 | 37056723 | PubTator, text mining | PubMed |
| Anaplastic transformation in thyroid cancer revealed by single-cell transcriptomics. | J Clin Invest | 2023 | 37053016 | PubTator, text mining | PubMed |
| Combating the challenges of COVID-19 pandemic: Insights into molecular mechanisms, immune responses and therapeutics against SARS-CoV-2. | Oxf Open Immunol | 2023 | 37051070 | PubTator, text mining | PubMed |
| Single-cell RNA sequencing highlights intratumor heterogeneity and intercellular network featured in adamantinomatous craniopharyngioma. | Sci Adv | 2023 | 37043580 | PubTator, text mining | PubMed |
| SARS-CoV-2 infection aggravates cigarette smoke-exposed cell damage in primary human airway epithelia. | Virol J | 2023 | 37041586 | PubTator, text mining | PubMed |
| Multimodal immunogenomic biomarker analysis of tumors from pediatric patients enrolled to a phase 1-2 study of single-agent atezolizumab. | Nat Cancer | 2023 | 37038005 | PubTator, text mining | PubMed |
| HMOX1 pathway signature predicts clinical benefit from immunotherapy plus tyrosine kinase inhibitor therapy in advanced renal cell carcinoma. | Cancer Med | 2023 | 37031459 | PubTator, text mining | PubMed |
| Specific human leukocyte antigen class I genotypes predict prognosis in resected pancreatic adenocarcinoma: a retrospective cohort study. | Int J Surg | 2023 | 37026827 | PubTator, text mining | PubMed |
| Favorable Immunotherapy Plus Tyrosine Kinase Inhibition Outcome of Renal Cell Carcinoma Patients with Low CDK5 Expression. | Cancer Res Treat | 2023 | 37024096 | PubTator, text mining | PubMed |
| Integrative single-cell sequencing analysis distinguishes survival-associated cells from the breast cancer microenvironment. | Cancer Med | 2023 | 37021816 | PubTator, text mining | PubMed |
| Analysis of Donor Pancreata Defines the Transcriptomic Signature and Microenvironment of Early Neoplastic Lesions. | Cancer Discov | 2023 | 37021392 | PubTator, text mining | PubMed |
| BET Inhibition Sensitizes Immunologically Cold Rb-Deficient Prostate Cancer to Immune Checkpoint Blockade. | Mol Cancer Ther | 2023 | 37014264 | PubTator, text mining | PubMed |
| Predictive and Prognostic Implications of Circulating CX3CR1+ CD8+ T Cells in Non-Small Cell Lung Cancer Patients Treated with Chemo-Immunotherapy. | Cancer Res Commun | 2023 | 37009132 | PubTator, text mining | PubMed |
| The immune cell landscape and response of Marek's disease resistant and susceptible chickens infected with Marek's disease virus. | Sci Rep | 2023 | 37005445 | PubTator, text mining | PubMed |
| Effect of Famotidine on COVID-19: Killing Virus or Opposing ARDS? | Pulm Ther | 2023 | 37004651 | PubTator, text mining | PubMed |
| T cell biomarkers come to the fore in cancer immunotherapy. | Cell Rep Med | 2023 | 37001529 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/3003/papers?page=37